NCT07340073Not yet recruitingPhase 1
Coordinated Reset Deep Brain Stimulation for Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
Deep brain stimulation (DBS) is a surgical implant procedure for the treatment of Parkinson's Disease (PD) utilizing medical devices approved by the FDA. A novel approach to current DBS approaches is called "Coordinated Reset" DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS (T-DBS) that uses continuous high amplitude and high frequency stimulation. This study will evaluate the safety and short-term efficacy of CR-DBS in PD. The results from this study will significantly advance the development of CR-DBS for the treatment of PD. Findings in this study will also provide the rationale for further development of this novel DBS approach for other neurological and psychiatric disorders.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 13 Nov 2025
- Start date
- 1 Dec 2026
- Primary completion date
- 1 Jan 2031
- Lead sponsor
- University of Minnesota
- Diseases
- Parkinson disease
- NCT number
- NCT07340073
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 24
- From 1 Dec 2026 to the primary completion date, 1 Jan 2031
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of musculoskeletal disorders that affect movement of the limbs/gait
- Other significant neurological disorder
- Significant psychiatric disorder
- History of dementia or cognitive impairment that precludes them from getting DBS surgery or per study staff judgment, MacCAT-CR assessment does not deduce that the participant has capacity to consent
- Other significant medical disorder that could impede study participation
Other
- Pregnant women
Who the study is looking for
- Diagnosis of Idiopathic Parkinson's Disease
- Minimum age of 21 years old
- Will be or has been implanted with the Boston Scientific Vercise Genus Rechargeable DBS system
Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.